Anticancer drug teaches unruly cells to toe the line

Charles, Dan
September 1991
New Scientist;9/7/91, Vol. 131 Issue 1785, p29
Reports on a drug developed in the U.S. that teaches cancer cells to behave like mature cells rather than ones which proliferate wildly. Difference from other drug cancer drugs which attempt to kill unruly cells; Compound developed by researchers at Columbia University and the Memorial Sloan-Kettering Cancer Center; Disclosure of findings at a meeting of the American Chemical Society in New York.


Related Articles

  • Evolution of Anticancer Drug Discovery and the Role of Cell-Based Screening. Balis, Frank M. // JNCI: Journal of the National Cancer Institute;1/16/2002, Vol. 94 Issue 2, p78 

    Editorial. Focuses on the development of the anticancer drug. Evolution of the anticancer drug; Role of cell-based screening to the development of the drugs; Aim on the development of molecularly targeted drugs.

  • Managing Patients Through Aggressive Cancer Therapies.  // ONS News;Sep2004 Supplement, Vol. 19, p33 

    The article discusses the strategies to prevent or reduce the incidence and severity of toxicities of aggressive cancer therapies. It focuses the serious complications and problems associated with treatment and management of patients with head and neck cancer. It highlights the use of...

  • Study examines cancer drug for Alzheimer's disease.  // Psychiatric Annals;Jan2005, Vol. 35 Issue 1, p21 

    Reports on a study from the University of Pennsylvania which found that paclitaxel improves strength and cell function among mice with a certain type of nerve cell damage common in Alzheimer's disease. Other diseases in which paclitaxel could be used.

  • Quality of life after cytotoxic chemotherapy: discussion paper. Priestman, T. J. // Journal of the Royal Society of Medicine;Jun1984, Vol. 77 Issue 6, p492 

    The article presents a discussion paper on the impact of cytotoxic chemotherapy on patient's quality of life. It is cited that the aim of cytotoxic chemotherapy is to destroy the tumor before the drugs kill the patient. The inability of cytotoxic drugs to distinguish between normal and malignant...

  • Proliferation of Walker 256 Carcinosarcoma Cells: Effect of Whole-Body Hyperthermia and Antitumor Agents. Lushnikova, E.; Ovsyanko, E.; Nepomnyashchikh, L.; Efremov, A.; Morozov, D. // Bulletin of Experimental Biology & Medicine;Nov2011, Vol. 152 Issue 1, p146 

    We studied the main biological characteristics of spontaneous growth of Walker 256 carcinosarcoma and under conditions of antitumor therapy. A combination of whole-body hyperthermia and cytostatic treatment (cyclophosphamide and melatonin) produced maximum suppression of the tumor growth,...

  • Killing cancer cells by targeted drug-carrying phage nanomedicines. Bar, Hagit; Yacoby, Iftach; Benhar, Itai // BMC Biotechnology;2008, Vol. 8, Special section p1 

    Background: Systemic administration of chemotherapeutic agents, in addition to its anti-tumor benefits, results in indiscriminate drug distribution and severe toxicity. This shortcoming may be overcome by targeted drug-carrying platforms that ferry the drug to the tumor site while limiting...

  • Zeroing in on Cancer. Amábile-Cuevas, Carlos F. // American Scientist;Sep/Oct2010, Vol. 98 Issue 5, p366 

    The article focuses on the development of cancer therapies and anticancer drugs. It states that the nature of cancer presents a difficulty in developing a unified model and therapy for cancer biology. Cancer cells have the capability of duplicating and becoming exotic cells. In the early...

  • Role of Alpha1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL (supra)+ Leukemic... Gambacorti-Passerini, Carlo; Barni, Rossella // JNCI: Journal of the National Cancer Institute;10/18/2000, Vol. 92 Issue 20, p1641 

    Describes the molecular characterization of a murine model for in vivo resistance to the antineoplastic drug STI571. Treatment of three groups of nude mice with STI571 beginning one day, eight days or 15 days after they were injected with human leukemic tumor cells; Evidence that alpha1 acid...

  • Clusterin Interacts with Paclitaxel and Confer Paclitaxel Resistance in Ovarian Cancer. Dong Choon Park; Seung Geun Yeo; Wilson, Mark R.; Yerbury, Justin J.; Kwong, Joseph; Welch, William R.; Yang Kyu Choi; Birrer, Michael J.; Mok, Samuel C.; Kwong-Kwok Wong // Neoplasia;Sep2008, Vol. 10 Issue 9, p964 

    Optimal debulking followed by chemotherapy is the standard treatment of managing late-stage ovarian cancer, but chemoresistance is still a major problem. In this study, we compared expression profiles of primary tumor tissue from five long-term (>8 years) and five short-term (<2 years) ovarian...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics